Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the
FDA accepts Regeneron and Sanofi's resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 and older, with a decision expected by April 18, 2025. The resubmission includes pivotal data confirming Dupixent's significant reduction in itch and hive activity, supported by the LIBERTY-CUPID Phase 3 clinical program. If approved, Dupixent would be the first targeted therapy for CSU in a decade.
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
FDA accepts Dupixent sBLA for chronic spontaneous urticaria treatment, with pivotal data showing significant itch and hive reduction. Decision expected by April 18, 2025, potentially marking the first targeted therapy for CSU in a decade.
Press Release: Dupixent sBLA accepted for FDA review for
FDA accepts Dupixent sBLA for chronic spontaneous urticaria, with a decision expected by April 18, 2025. New data confirm Dupixent significantly reduces itch and hive activity, potentially offering the first targeted therapy for CSU in a decade.
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030
Global Organoids Market to grow at a CAGR of ~14% by 2030, driven by personalized medicine, organoid use in drug discovery, and cancer research. North America leads the market, with key players including Thermofisher Scientific Inc., StemCell Technologies Inc., and others. Organoids mimic human organs, aiding in disease modeling and drug testing, but face challenges like high costs and limited vascularization.
Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial
IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody therapeutic for peanut allergy, in the ACCELERATE Peanut phase 1 clinical trial. The trial aims to assess safety, tolerability, and proof of mechanism in patients aged 15 years and older. IGNX001 attaches to peanut proteins to neutralize them, differing from other immunotherapies like Palforzia and Xolair. The trial is ongoing in Australia, with recruitment targeting older adolescents and adults, and initial results expected mid-2025.
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over
Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy
Professor Nancy Ip discusses her neuroscience research, focusing on neurotrophic factors, immune modulation, brain signaling pathways, and the potential of traditional Chinese medicine in treating Alzheimer’s disease. She highlights the importance of new technologies and precision medicine in shaping future Alzheimer’s research and emphasizes the need for lifelong brain health.
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift
FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.
Biotechnology Market Value Set to Reach $2,667.36 Billion
The global biotechnology market is projected to reach $550.83 billion in 2024 and $2667.36 billion by 2034, driven by advancements in synthetic biology, CRISPR, and genomic sequencing. North America is expected to lead, with a revenue of $231.68 billion in 2024, due to established agricultural biotechnology and a robust GMO framework. Key players include Johnson & Johnson, Roche, Pfizer, and Novartis.
© Copyright 2024. All Rights Reserved by MedPath